Sally is one of Bird & Bird's most experienced intellectual property partners, specialising in transactional IP matters. She offers a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance. Providing the full array of commercial advice and support in IP, she leads the team delivering licensing, partnering and exploitation agreements, and research, development and marketing collaborations. She also advises clients on regulatory and 'freedom to operate' issues, and manage significant due diligence matters. Before joining Bird & Bird in 2006, she was head of IP & Life Sciences at another global law firm, after spending 11 years in-house firstly as senior legal adviser at ICI/Zeneca and latterly as Legal Director of Novartis UK. She has been given a number of accolades, including recognition as a market leader in Chambers and Legal 500, named as "a leading woman in IP" (WIPR) and rated as "highly recommended" in Who's Who Legal: Life Sciences. Most recently she was named by WIPR as "one of the most influential IP lawyers in the world". She is the editor of the Kluwer law publication "The EU Guide to EU Pharmaceutical Regulatory Law".